<i>SETD2</i>基因与骨髓增生异常综合征的相关研究

彭真萍; 李佳明; 陈玉宝; 王莹; 严泽莹; 刘之茵; 孙海敏; 陈欣洁; 安然; 陈钰

doi:10.13201/j.issn.1004-2806.2020.11.010

SETD2基因与骨髓增生异常综合征的相关研究

- 1. 上海交通大学医学院附属瑞金医院北院检验科(上海, 201801);
- 2. 上海交通大学医学院附属瑞金医院北院血液科
基金项目:
国家青年科学基金项目(No:81900129)

详细信息

通讯作者: 李佳明,E-mail:lijiaming007007@126.com

中图分类号: R733

收稿日期: 2020-07-28

Association of SETD2 gene mutations with myelodysplastic syndrome

- 1 Department of Clinical Laboratory, Ruijin Hospital North Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201801, China;
- 2 Department of Hematology, Ruijin Hospital North Affiliated to Shanghai Jiaotong University School of Medicine

More Information

Corresponding author: LI Jia-ming, E-mail: lijiaming007007@126.com

Received Date: 28 July 2020

摘要

摘要: 目的:探讨SETD2基因与骨髓增生异常综合征（MDS）相关临床预后的关系。方法:应用靶向二代基因测序技术,检测我院180例MDS患者的43个MDS相关基因,并观察SETD2基因对患者原始细胞、血红蛋白、生存时间、无进展生存时间以及治疗效果的影响。结果:180例MDS患者中,我们发现SETD2基因突变包括SETD2 p.L2486R,SETD2 p.E1142G,TET2 p.T2388fs和SETD2 p.F1116fs;单核苷酸多态性包括SETD2 p.M761I,SETD2 p.E639K,SETD2 p.P193L,SETD2 p.M1080I,SETD2 p.N1155K和SETD2 p.P1962L,其中,SETD2 p.M761I,SETD2 p.E639K,SETD2 p.P193L和SETD2 p.M1080I四种SNP位点经预测分析具有危害性和致病性。携带危害性SETD2基因异常的患者共14例,其中同时携带TP53基因突变者占50.0%,同时携带TET基因突变者占28.6%,同时携带ASXL1基因突变者占21.4%。携带SETD2基因异常的MDS患者表现为较高的原始细胞水平（P＜0.05）;并且单变量和多变量生存分析表明,SETD2基因异常与MDS患者总生存时间和无进展生存时间显著相关（P＜0.05）。结论:SETD2基因异常与MDS疾病进展迅速以及不良预后密切相关。
- 基因突变 /
- 骨髓增生异常综合征 /
- 无进展生存 /
- SETD2
Abstract: Objective:To investigate the effect of SETD2 gene mutations on clinical features and prognosis in patients with myelodysplastic syndrome（MDS）.Method:Next-generation sequencing covering 43 genes was performed using samples from 180 patients with newly diagnosed MDS,and the association of SETD2 variants with blast cells,hemoglobin,overall survival,progression-free survival and the response to treatment was analyzed.Result:In 180 patients with MDS,SETD2 mutations were included p.L2486 R,p.E1142 G,p.T2388 fs and p.F1116 fs.Single nucleotide variants included p.M761 I,p.E639 K,p.P193 L,p.M1080 I,p.N1155 K and p.P1962 L.SETD2 p.M761 I,p.E639 K,p.P193 L and p.M1080 I were predicted to pathogenic SNP using the software tools.Fourteen patients carried the hazardous SETD2 gene variants,and they exhibited a significantly increased frequency of TP53 gene alterations（50.0%）,TET2（28.6%）and ASXL1 gene mutations（21.4%）.MDS patients with SETD2 gene variants showed higher blast cell counts,in addition（P＜0.05）.Both univariate and multivariate survival analyses indicated that SETD2 gene variants were significantly associated with poor overall survival and progression-free survival（P＜0.05）.Conclusion:Our observations show that SETD2 gene variants are associated with rapid progression to leukemia and poor outcomes in patients with MDS.
- gene mutation /
- myelodysplastic syndrome /
- progression-free survival /
- SET domain containing

HTML全文

参考文献(31)

[1]	Greenberg PL,Stone RM,Al-Kali A,et al.Myelodysplastic Syndromes,Version 2.2017,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2017,15:60-87.
[2]	Tefferi A,Lasho TL,Patnaik MM,et al.Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R[J].Am J Hematol,2017,92:1311-1317.
[3]	Kim T,Tyndel MS,Kim HJ,et al.The clonal origins of leukemic progression of myelodysplasia[J].Leukemia,2017,31:1928-1935.
[4]	Hospital MA,Vey N.Myelodysplastic Syndromes:How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation[J].Curr Oncol Rep,2020,22:4.
[5]	Visconte V,Nakashima MO,Rogers HJ.Mutations in splicing factor genes in myeloid malignancies:significance and impact on clinical features[J].Cancers,2019,11:1844.
[6]	Tlemsani C,Luscan A,Leulliot N,et al.SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort[J].J Med Genet,2016,53:743-751.
[7]	Baubec T,Colombo DF,Wirbelauer C,et al.Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation[J].Nature,2015,520:243-247.
[8]	Tiedemann RL,Hlady RA,Hanavan PD,et al.Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma[J].Oncotarget,2016,7:1927-1946.
[9]	Imielinski M,Berger AH,Hammerman PS,et al.Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing[J].Cell,2012,150:1107-1120.
[10]	Zhang YL,Sun JW,Xie YY,et al.Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation[J].Cell Res,2018,28:476-490.
[11]	Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127:2391-2405.
[12]	Cheson BD,Greenberg PL,Bennett JM,et al.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J].Blood,2006,108:419-425.
[13]	Fahey CC,Davis IJ.SETting the stage for cancer development:SETD2 and the consequences of lost methylation[J].Cold Spring Harb Perspect Med,2017,7:a026468.
[14]	McDaniel SL,Strahl BD.Shaping the cellular landscape with Set2/SETD2 methylation[J].Cell Mol Life Sci,2017,74:3317-3334.
[15]	Kim IK,McCutcheon JN,Rao G,et al.Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer[J].Oncogene,2019,38:180-193.
[16]	Tessema M,Rossi MR,Picchi MA,et al.Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers[J].Lung Cancer,2018,123:99-106.
[17]	Sakthikumar S,Elvers I,Kim J,et al.SETD2 is recurrently mutated in whole-exome sequenced canine osteosarcoma[J].Cancer Res,2018,78:3421-3431.
[18]	Mar BG,Bullinger LB,McLean KM,et al.Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia[J].Nat Commun,2014,5:3469.
[19]	Wang Q,Cheng T.Evidences for mutations in the histone modifying gene SETD2 as critical drivers in leukemia development[J].Sci China Life Sci,2014,57:944-946.
[20]	Masetti R,Castelli I,Astolfi A,et al.Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing[J].Oncotarget,2016,7:56746-56757.
[21]	Parker H,Rose-Zerilli MJ,Larrayoz M,et al.Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia[J].Leukemia,2016,30:2179-2186.
[22]	Vallois D,Roberti A,Bisig B,et al.Molecular oncogenesis of lymphomas:role of the SETD2 gene in intestinal T-cell lymphomas[J].Med Sci,2017,33:469-473.
[23]	Mehdi A,Riazalhosseini Y.Epigenome Aberrations:Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma[J].Int J Mol Sci,2017,18:1774.
[24]	Kim JY,Yu JH,Nam SJ,et al.Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast[J].Transl Oncol,2017,11:18-23.
[25]	Wang S,Yuan X,Liu Y,et al.Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients[J].J Transl Med,2019,17:101.
[26]	Visconte V,Nakashima MO,Rogers HJ.Mutations in splicing factor genes in myeloid malignancies:significance and impact on clinical features[J].Cancers,2019,11:1844.
[27]	Sidaway P.Haematological cancer:TP53 mutations sensitize to decitabine[J].Nat Rev Clin Oncol,2017,14:72.
[28]	Carvalho S,Vítor AC,Sridhara SC,et al.SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint[J].Elife,2014,3:e02482.
[29]	Xie P,Tian C,An L,et al.Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes[J].Cell Signal,2008,20:1671-1678.
[30]	Neri F,Rapelli S,Krepelova A,et al.Intragenic DNA methylation prevents spurious transcription initiation[J].Nature,2017,543:72-77.
[31]	Mar BG,Chu SH,Kahn JD,et al.SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia[J].Blood,2017,130:2631-2641.